Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 7.21%-2.14M | 49.70%-2.07M | 35.65%-2.32M | 52.16%-12.4M | 35.55%-2.37M | 58.38%-2.3M | 49.46%-4.12M | 57.85%-3.61M | 55.10%-25.91M | 75.63%-3.68M |
| Net income from continuing operations | 18.58%-2.49M | 30.57%-3.26M | 25.42%-4.05M | 46.57%-15.29M | 54.54%-2.11M | 43.30%-3.06M | 26.70%-4.69M | 55.43%-5.43M | 53.57%-28.62M | 63.65%-4.64M |
| Operating gains losses | 213.75%1.1K | 5.56%1.2K | -104.59%-383 | 217.83%65.91K | 181.22%56.09K | -46.55%349 | -83.75%1.13K | 52.12%8.34K | ---55.94K | ---69.06K |
| Depreciation and amortization | 4.40%111.46K | 1.41%106.98K | 0.86%107.88K | -11.21%425.06K | -7.12%105.84K | 4.10%106.77K | -27.52%105.49K | -8.33%106.96K | 73.52%478.75K | 16.68%113.96K |
| Remuneration paid in stock | -98.38%4.25K | 54.48%269.1K | -40.78%1.65M | 31.25%3.19M | -106.28%-30.93K | -64.63%262.35K | -69.13%174.2K | 339.57%2.79M | -58.65%2.43M | 76.80%492.49K |
| Deferred tax | ---- | ---- | ---- | 111.92%25.58K | --25.58K | --0 | --0 | --0 | -0.25%-214.61K | --0 |
| Other non cashItems | -2,363.89%-10.6K | 9,113.83%682.01K | -23.38%6.04K | -63.56%23.59K | -77.66%7.84K | -94.35%468 | -29.76%7.4K | -27.24%7.88K | 192.61%64.73K | 240.44%35.08K |
| Change In working capital | -35.74%249.81K | -55.51%128.01K | 96.64%-36.61K | -93,812.32%-838.64K | -210.29%-426.62K | 142.75%388.78K | 112.00%287.75K | -137.28%-1.09M | 99.96%-893 | 115.42%386.82K |
| -Change in receivables | -28.90%63.2K | 41.37%-25.86K | -67.40%74.55K | -92.98%192.23K | -91.10%-81.23K | -11.88%88.89K | -124.74%-44.11K | -91.54%228.68K | 213.94%2.74M | 96.38%-42.51K |
| -Change in prepaid assets | -109.70%-15.17K | -165.79%-79.56K | 122.21%24.99K | -31.62%262.32K | -32.74%97.6K | 81.97%156.33K | -82.79%120.94K | 79.54%-112.54K | 154.43%383.63K | 1,285.19%145.1K |
| -Change in payables and accrued expense | 40.56%201.78K | 10.67%233.43K | 88.70%-136.16K | 58.61%-1.29M | -255.85%-442.98K | 113.10%143.56K | 106.85%210.92K | -256.79%-1.2M | -392.68%-3.12M | 121.11%284.23K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 7.21%-2.14M | 49.70%-2.07M | 35.65%-2.32M | 52.16%-12.4M | 35.55%-2.37M | 58.38%-2.3M | 49.46%-4.12M | 57.85%-3.61M | 55.10%-25.91M | 75.63%-3.68M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 63.20%-117.62K | 46.98%-335.45K | 65.51%-186.86K | 65.02%-1.77M | 75.45%-275.01K | 67.01%-319.63K | 47.70%-632.72K | 69.20%-541.75K | 60.77%-5.06M | 59.47%-1.12M |
| Capital expenditure reported | 55.03%-133.48K | 79.42%-129.61K | 65.51%-186.86K | 51.31%-1.74M | 59.13%-275.27K | 65.35%-296.81K | 21.25%-629.73K | 56.70%-541.75K | 63.82%-3.58M | 59.95%-673.58K |
| Net PPE purchase and sale | 99.68%-74 | ---- | ---- | 98.27%-25.54K | 100.06%265 | 79.69%-22.82K | 99.27%-2.99K | --0 | 36.00%-1.48M | -13.61%-446.66K |
| Net other investing changes | --171.16K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 63.20%-117.62K | 46.98%-335.45K | 65.51%-186.86K | 65.02%-1.77M | 75.45%-275.01K | 67.01%-319.63K | 47.70%-632.72K | 69.20%-541.75K | 60.77%-5.06M | 59.47%-1.12M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 346.62%5.86M | -493.66%-66.92K | 6,441.58%3.87M | -72.21%3.04M | -68.43%1.77M | 724.33%1.31M | 129.53%17K | -101.09%-60.96K | -77.97%10.93M | -47.00%5.61M |
| Net issuance payments of debt | -10.27%-70.37K | -8.98%-66.92K | -5.63%-64.4K | 36.96%-249.75K | 11.62%-63.57K | 69.62%-63.81K | -6.69%-61.4K | -7.60%-60.96K | -170.22%-396.17K | -68.79%-71.93K |
| Net common stock issuance | --6.51M | --0 | --4M | -43.09%3.31M | --3.31M | --0 | --0 | --0 | -86.09%5.82M | ---- |
| Proceeds from stock option exercised by employees | --0 | ---- | ---- | -98.61%78.4K | --0 | --0 | --78.4K | --0 | -48.45%5.65M | --0 |
| Net other financing activities | ---581.74K | --0 | ---69.71K | 25.95%-104.1K | ---1.48M | ---- | ---- | ---- | 95.34%-140.58K | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 346.62%5.86M | -493.66%-66.92K | 6,441.58%3.87M | -72.21%3.04M | -68.43%1.77M | 724.33%1.31M | 129.53%17K | -101.09%-60.96K | -77.97%10.93M | -47.00%5.61M |
| Net cash flow | ||||||||||
| Beginning cash position | -55.14%2.62M | -51.52%5.09M | -74.96%3.68M | -57.78%14.71M | -66.39%4.61M | -71.40%5.84M | -65.22%10.5M | -57.78%14.71M | -37.52%34.84M | -66.83%13.7M |
| Current changes in cash | 374.90%3.6M | 47.74%-2.47M | 132.24%1.36M | 44.46%-11.13M | -207.56%-874K | 80.47%-1.31M | 49.73%-4.73M | 10.91%-4.21M | 4.43%-20.04M | 111.18%812.55K |
| Effect of exchange rate changes | -71.75%21.96K | -95.39%3.43K | 1,506.78%47.11K | 210.98%101.59K | -124.12%-47.19K | 2,840.82%77.76K | 121.06%74.37K | -104.86%-3.35K | -303.72%-91.54K | -75.41%195.6K |
| End cash Position | 35.57%6.24M | -55.14%2.62M | -51.52%5.09M | -74.96%3.68M | -74.96%3.68M | -66.39%4.61M | -71.40%5.84M | -65.22%10.5M | -57.78%14.71M | -57.78%14.71M |
| Free cash from | 13.43%-2.27M | 49.34%-2.41M | 39.55%-2.51M | 54.26%-14.17M | 44.86%-2.65M | 59.66%-2.62M | 49.24%-4.75M | 59.79%-4.15M | 55.71%-30.97M | 72.05%-4.8M |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.